BDC - Venture Capital and the Fonds de solidarité FTQ are pleased to announce a US$30-million commitment to Sanderling Ventures, an investment firm with a 35-year track record of building new biomedical companies. As a result of this transaction, Sanderling will create a permanent facility for the development of early-stage life science projects in Montréal, Canada. The dollars committed by BDC and the Fonds will be placed in a Canadian parallel fund to Sanderling Ventures Fund VII, which is well on its way to achieving its target size of US$250 million.
Image Courtesy of ddpavumba / FreeDigitalPhotos.net
To read the full, original article click on this link: US$30M Commitment Lures Major Biomedical Investor to Setup Life Science Development Centre in Montréal - Press Release - Digital Journal
